The MARCH family of membrane-bound E3 ubiquitin ligases comprises a group of proteins known for their role in the ubiquitination process, which marks proteins for degradation or alters their function. MARCH proteins are involved in the regulation of a variety of cellular processes, particularly those related to the immune system, such as antigen presentation and immune signaling. They function by adding ubiquitin molecules to specific target proteins, typically membrane proteins, leading to their internalization, trafficking, and sometimes degradation. This ubiquitination process is crucial for maintaining cellular homeostasis and regulating the abundance and activity of key cell surface receptors and molecules. MARCH family members, through their ligase activity, can influence signaling pathways, and their dysregulation is implicated in various diseases, including cancers and immune disorders. Additionally, the MARCH family plays a role in viral immune evasion, as some viruses have evolved MARCH-like proteins to downregulate immune molecules on the host cell surface.
Targeting the MARCH family of E3 ubiquitin ligases with small molecules for disruption or inhibition can significantly advance the understanding of their mechanistic roles in cellular processes. Inhibition of MARCH proteins allows for the study of how the controlled degradation and regulation of membrane proteins affect cell signaling and immune responses. By inhibiting the ubiquitination of specific target proteins, researchers can observe the resultant changes in cellular pathways, particularly in the context of immune cell activation and antigen presentation.
Siehe auch...
Artikel 1 von 10 von insgesamt 19
Anzeigen:
| Produkt | CAS # | Katalog # | Menge | Preis | Referenzen | Bewertung |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin hemmt MARCH, indem es die HMG-CoA-Reduktase, ein Schlüsselenzym der Cholesterinsynthese, blockiert, was zu einer Verringerung des Cholesterinspiegels in den Zellen führt. Ein niedrigerer Cholesterinspiegel verringert die Aktivierung von MARCH. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Lovastatin hemmt wie Simvastatin die HMG-CoA-Reduktase, wodurch der zelluläre Cholesterinspiegel gesenkt und indirekt die Aktivierung von MARCH gehemmt wird. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $68.00 $159.00 $772.00 | 2 | |
Pravastatin hemmt die Cholesterinsynthese, indem es auf die HMG-CoA-Reduktase abzielt, was die MARCH-Aktivierung aufgrund des reduzierten Cholesterinspiegels beeinflussen kann. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin hemmt die HMG-CoA-Reduktase, reduziert die Cholesterinproduktion und hemmt in der Folge die MARCH-Aktivierung. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $142.00 | 8 | |
Rosuvastatin hemmt die HMG-CoA-Reduktase, was zu einer verringerten Cholesterinsynthese und einer möglichen Hemmung von MARCH führt. | ||||||
Simvastatin, Sodium Salt | 12009-77-6 | sc-222312 | 5 mg | $162.00 | 6 | |
Simvastatin-Natrium ist eine Salzform von Simvastatin und wirkt über denselben Mechanismus, indem es die HMG-CoA-Reduktase hemmt und den Cholesterinspiegel senkt. | ||||||
Cerivastatin, Sodium Salt | 143201-11-0 | sc-207418 | 2.5 mg | $175.00 | ||
Cerivastatin hemmt die HMG-CoA-Reduktase, was zu einer verringerten Cholesterinproduktion führt, was sich auf die MARCH-Aktivierung auswirken kann. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin-Natrium, eine Salzform von Fluvastatin, hemmt die HMG-CoA-Reduktase und beeinflusst möglicherweise MARCH durch Cholesterinsenkung. | ||||||
Fluvastatin, Sodium Salt | 93957-55-2 | sc-202613 sc-202613A sc-202613B | 25 mg 50 mg 100 mg | $91.00 $135.00 $241.00 | 1 | |
Lovastatin-Natrium, eine Salzform von Lovastatin, hemmt die HMG-CoA-Reduktase und beeinflusst indirekt die MARCH-Aktivität durch Cholesterinreduktion. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $98.00 $140.00 $306.00 $459.00 $1224.00 $1958.00 | 1 | |
Beeinflusst, ähnlich wie Thalidomid und Lenalidomid, die Ubiquitin-Ligase-Aktivität. | ||||||